NSDHL Inhibitors
NSDHL (NAD(P) dependent steroid dehydrogenase-like) is a critical enzyme involved in cholesterol biosynthesis. It plays a pivotal role in the conversion of lanosterol to cholesterol within cells. This conversion occurs in the endoplasmic reticulum and is a fundamental step in the mevalonate pathway, which is responsible for generating cholesterol and other essential molecules. NSDHL's enzymatic activity is crucial for maintaining proper cholesterol levels, which are vital for various cellular processes, including cell membrane integrity, hormone synthesis, and signaling. Dysregulation of NSDHL can lead to cholesterol-related disorders, underscoring its importance in cellular homeostasis.
NSDHL inhibitors target the enzymatic activity of NSDHL, disrupting its role in cholesterol biosynthesis. These inhibitors are explored for their possible applications, particularly in conditions where modulating cholesterol levels is desirable. By inhibiting NSDHL, researchers aim to impact cholesterol metabolism and related pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Itraconazole | 84625-61-6 | sc-205724 sc-205724A | 50 mg 100 mg | $78.00 $142.00 | 23 | |
Itraconazole is an antifungal agent in research that has been shown to inhibit cholesterol biosynthesis by targeting enzymes in the mevalonate pathway, including NSDHL. | ||||||
Ketoconazole | 65277-42-1 | sc-200496 sc-200496A | 50 mg 500 mg | $63.00 $265.00 | 21 | |
Ketoconazole, another antifungal drug, can affect cholesterol biosynthesis by inhibiting enzymes in the mevalonate pathway, including NSDHL. | ||||||
Mevastatin (Compactin) | 73573-88-3 | sc-200853 sc-200853A | 10 mg 50 mg | $77.00 $179.00 | 18 | |
Compactin, also known as mevastatin, is a compound that inhibits HMG-CoA reductase, an enzyme upstream of NSDHL in the cholesterol biosynthesis pathway. By reducing the availability of substrates, it can indirectly affect NSDHL activity. | ||||||